This is a first-in-human study to evaluate the feasibility, safety and preliminary antitumor
efficacy of autologous T cells genetically engineered with a CD19/CD22-specific chimeric
antigen receptor (CAR) and manufactured with a new process. CAR-T cells will be investigated
as single agent in pediatric and adult acute lymphoblastic leukemia (ALL).